Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies. It also engages in the preclinical development of other drug candidates, including other STAT3 inhibitors and compounds targeting the metabolism of tumors. The company also has a strategic collaboration with the University of Bergen to develop immune stimulation drug; and the Emory University to enable expanded cancer research on WP1066 molecule for the treatment of medulloblastoma, a pediatric malignant primary brain tumor. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone713-300-5160
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees8
OptionableNot Optionable
Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions
What is Moleculin Biotech's stock symbol?
Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."
How were Moleculin Biotech's earnings last quarter?
Moleculin Biotech Inc (NASDAQ:MBRX) released its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.05. View Moleculin Biotech's Earnings History.
When is Moleculin Biotech's next earnings date?
What price target have analysts set for MBRX?
2 brokers have issued 1 year price targets for Moleculin Biotech's stock. Their predictions range from $3.00 to $8.00. On average, they expect Moleculin Biotech's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 292.6% from the stock's current price. View Analyst Price Targets for Moleculin Biotech.
What is the consensus analysts' recommendation for Moleculin Biotech?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Moleculin Biotech.
What are Wall Street analysts saying about Moleculin Biotech stock?
Here are some recent quotes from research analysts about Moleculin Biotech stock:
- 1. Maxim Group analysts commented, "Moleculin announced that it has begun recruiting patients in its second clinical trial of Annamycin for the treatment of relapsed/refractory acute myeloid leukemia. This study is being conducted in Poland. We see this as a positive for the company." (1/9/2019)
- 2. According to Zacks Investment Research, "Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX. " (10/19/2018)
Has Moleculin Biotech been receiving favorable news coverage?
News articles about MBRX stock have trended very positive recently, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Moleculin Biotech earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Are investors shorting Moleculin Biotech?
Moleculin Biotech saw a increase in short interest in the month of December. As of December 14th, there was short interest totalling 1,360,986 shares, an increase of 36.2% from the November 30th total of 999,301 shares. Based on an average daily trading volume, of 1,350,419 shares, the short-interest ratio is presently 1.0 days. Currently, 6.7% of the shares of the stock are sold short. View Moleculin Biotech's Current Options Chain.
Who are some of Moleculin Biotech's key competitors?
Some companies that are related to Moleculin Biotech include CytoDyn (CYDY), MOTIF BIO PLC/S (MTFB), Emisphere Technologies (EMIS), Poxel (PXXLF), REDHILL BIOPHAR/S (RDHL), Bellicum Pharmaceuticals (BLCM), Millendo Therapeutics (MLND), Syndax Pharmaceuticals (SNDX), Ardelyx (ARDX), Spero Therapeutics (SPRO), Chimerix (CMRX), Adamis Pharmaceuticals (ADMP), Galmed Pharmaceuticals (GLMD), Imprimis Pharmaceuticals (IMMY) and OASMIA PHARMACE/ADR (OASM).
Who are Moleculin Biotech's key executives?
Moleculin Biotech's management team includes the folowing people:
- Mr. Walter V. Klemp, Founder, Chairman, CEO & Pres (Age 58)
- Mr. Jonathan P. Foster, CFO & Exec. VP (Age 54)
- Dr. Donald H. Picker, Chief Scientific Officer (Age 72)
- Ms. Jacqueline Northcut, Consultant (Age 56)
- Dr. Waldemar Priebe, Co-Founder and Chairman of Scientific Advisory Board
How do I buy shares of Moleculin Biotech?
Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Moleculin Biotech's stock price today?
One share of MBRX stock can currently be purchased for approximately $1.4010.
How big of a company is Moleculin Biotech?
Moleculin Biotech has a market capitalization of $38.52 million. The company earns $-9,800,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Moleculin Biotech employs 8 workers across the globe.
What is Moleculin Biotech's official website?
How can I contact Moleculin Biotech?
Moleculin Biotech's mailing address is 2575 WEST BELLFORT SUITE 333, HOUSTON TX, 77054. The company can be reached via phone at 713-300-5160.
MarketBeat Community Rating for Moleculin Biotech (NASDAQ MBRX)
MarketBeat's community ratings are surveys of what our community members think about Moleculin Biotech and other stocks. Vote "Outperform" if you believe MBRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
